COMMUNIQUÉS West-GlobeNewswire

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
07/10/2025
FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for [...]
Prenetics Completes $72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8’s Path to $100 Million ARR
07/10/2025
Strengthens Balance Sheet with Over $60 Million in Cash 1 , Excluding Bitcoin Treasury David Beckham Co-Founded IM8 on Track to Achieve $100 Million ARR in First Year, Becoming One of the Fastest-Growing Supplement [...]
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
07/10/2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc [...]
GATC Health Announces Launch of Derisq: The Definitive AI Report for Predictive Risk Assessment of Drug Candidates at Fierce Biotech Week 2025
07/10/2025
Derisq delivers actionable insights about drug safety, efficacy and off-target risks prior to committing development capital BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GATC Health, a leading tech-bio company leveraging [...]
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
07/10/2025
MELBOURNE, Australia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing treatments for recurring and metastatic [...]
MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets
07/10/2025
MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc [...]
Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®
07/10/2025
Nausea and Vomiting Are the Most Frequent Reasons for Discontinuing GLP-1 Therapies, Significantly Impacting Adherence, Titration and Preventing Achievement of Proven Long-Term Benefits WOBURN, Mass., Oct. 07, 2025 ( [...]
Privia Health to Report Third Quarter 2025 Results on Thursday, November 6
07/10/2025
ARLINGTON, Va., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, [...]
Parexel Expands Global Site Alliance Program, Delivering 40% Faster Site Activation, 20% Faster Study Start Up Timelines and Four Times More Patient Enrollments Per Site
07/10/2025
Parexel’s Site Alliance Program strengthens global partnerships with clinical research sites and reinforces leadership in site engagement excellence RALEIGH, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading [...]
Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents
07/10/2025
The two new patents expand protection for Salipro Biotech's proprietary technology for stabilizing and extracting challenging membrane proteins, crucial for developing therapeutics against high-value drug targets like [...]
New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
07/10/2025
Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile Consistent efficacy demonstrated across age groups MILAN, Italy, October 07, [...]
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
07/10/2025
Torino, Italy, October 7 – Resalis Therapeutics , a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense [...]
Children’s National ranked top hospital in the nation by U.S. News & World Report
07/10/2025
Washington, DC, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Children’s National Hospital once again ranked among the nation’s best by U.S. News & World Report Ranked in all specialties, with top 10 honors in neurology and [...]
Scottish Rite for Children Ranked No. 1 for Pediatric Orthopedic Care by U.S. News & World Report
07/10/2025
Hospital has been recognized as one of the nation’s premier centers for 17 years Dallas, Oct. 07, 2025 (GLOBE NEWSWIRE) -- U.S. News & World Report ranked No. 1 in the nation for pediatric orthopedic care in its [...]
Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
07/10/2025
Single dose of avigbagene parvec (FLT201) demonstrates sustained clinical benefit and favorable safety up to two years after withdrawal of prior chronic therapy Data underscore potential to set new standard-of-care [...]
Carlsbad Dental Care Expands Access to Modern Dentistry with New Patient Special and Financing Options
07/10/2025
Carlsbad, CA, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Carlsbad Dental Care, a trusted local practice led by Dr. Raymond Ngo, is improving access to high-quality dental care for families across the Carlsbad community with its [...]
Allegro showcases superior shock-absorbing capacity of injectable hydrogel for osteoarthritis at CellMech
07/10/2025
Comparative testing against four market-leading hydrogels demonstrates Hydrocelin’s superior shock absorbing capacity Significantly improves the shock-absorbing capacity of pathological equine synovial fluid in [...]
Bioxodes nomme Philippe Monteyne, un vétéran de l’industrie pharmaceutique, au poste de président et accélère le développement en phase avancée de son candidat médicament innovant dans l’AVC
07/10/2025
Ancien dirigeant de GSK et de Sanofi, M. Monteyne a supervisé le développement de Cervarix ® et permis l’avancement de plusieurs traitements pionniers dans les maladies rares ; il apporte dix années d’expérience en [...]
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
07/10/2025
Former GSK and Sanofi executive, led Cervarix ® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalist Strengthens Bioxodes leadership following encouraging Phase 2a [...]

Pages